The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cancer-Derived Mutations in KEAP1 Impair NRF2 Degradation but not Ubiquitination
Open accessPublished version of a preprint
Abstract
NRF2 is a transcription factor that mediates stress responses. Oncogenic mutations in NRF2 localize to one of its two binding interfaces with KEAP1, an E3 ubiquitin ligase that promotes proteasome-dependent degradation of NRF2. Somatic mutations in KEAP1 occur commonly in human cancer, where KEAP1 may function as a tumor suppressor. These mutations distribute throughout the KEAP1 protein but little is known about their functional impact. In this study, we characterized 18 KEAP1 mutations defined in a lung squamous cell carcinoma tumor set. Four mutations behaved as wild-type KEAP1, thus are likely passenger events. R554Q, W544C, N469fs, P318fs, and G333C mutations attenuated binding and suppression of NRF2 activity. The remaining mutations exhibited hypomorphic suppression of NRF2, binding both NRF2 and CUL3. Proteomic analysis revealed that the R320Q, R470C, G423V, D422N, G186R, S243C, and V155F mutations augmented the binding of KEAP1 and NRF2. Intriguingly, these “super-binder” mutants exhibited reduced degradation of NRF2. Cell-based and in vitro biochemical analyses demonstrated that despite its inability to suppress NRF2 activity, the R320Q “superbinder” mutant maintained the ability to ubiquitinate NRF2. These data strengthen the genetic interactions between KEAP1 and NRF2 in cancer and provide new insight into KEAP1 mechanics. Cancer Res; 74(3); 808–17. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Specifically, we discover that the kelch-like protein KEAP1 and the transcriptional activator NRF2, mediate levels of PD-L1 upregulation after IFN γ stimulation.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citationKomatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., Sou, Y.-S., Ueno, I., Sakamoto, A., Tong, K. I., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2021 · Cited by 2,288
Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome
Finley, D. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081507.101607 · Cited by 1,764
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 1×
“Recent studies also establish a role for NRF2 in modulating anabolic pathways to suit the metabolic demands of cancer cell growth, effectively yielding an increase in cancer cell proliferation (6).”
Keap1 Is a Redox-Regulated Substrate Adaptor Protein for a Cul3-Dependent Ubiquitin Ligase Complex
Zhang, D. D., Lo, S., Cross, J. V., Templeton, D. J., & Hannink, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10941-10953.2004 · Cited by 1,284
Cullinan, S. B., Gordan, J. D., Jin, J., Harper, J. W., & Diehl, J. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8477-8486.2004 · Cited by 986
NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer
Hayes, J. D., & McMahon, M. J. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.12.008 · Cited by 870
Tong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759 · cited 1×
“Regardless of tissue origin, nearly all somatic mutations within NRF2 fall to either the ETGE or the DLG motif, two regulatory short amino acid sequences within NRF2 that contact KEAP1 (3).”
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Sundaram, S. K., Khazanov, N. A., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 759
Furukawa, M., & Xiong, Y. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.25.1.162-171.2005 · Cited by 759
Cited by
Sorted by citations
Items 101–138 of 138
Kinase signalling adaptation supports dysfunctional mitochondria in disease
Skalka, G., Tsakovska, M., & Murphy, D. J. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1354682 · Cited by 12
Jin, J., Luo, J., Jin, X., Lim, K. S., He, Y., Ding, J., Shen, Y., Hou, Y., Liu, H., Zhu, X., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0787 · Cited by 10
LaPak, K. M., Saeidi, S., Bok, I., Wamsley, N. T., Plutzer, I. B., Bhatt, D. P., Luo, J. R., Ashrafi, G., & Major, M. B. (2023) · Science Signaling · doi:10.1126/scisignal.adi9018 · Cited by 9
Self-citationPredicting drug response through tumor deconvolution by cancer cell lines
Hsu, Y.-C., Chiu, Y., Lu, T., Hsiao, T., & Chen, Y. (2024) · Patterns · doi:10.1016/j.patter.2024.100949 · Cited by 10
How to deal with frenemy NRF2: Targeting NRF2 for chemoprevention and cancer therapy
Tang, Y.-C., Chuang, Y., Chang, H.-H., Juang, S., Yen, G., Chang, J.-Y., & Kuo, C. (2023) · Journal of Food and Drug Analysis · doi:10.38212/2224-6614.3463 · Cited by 11
New findings about human dipeptidyl peptidase III based on mutations found in cancer
Matovina, M., Agić, D., Abramić, M., Matić, S., Karačić, Z., & Tomić, S. (2017) · RSC Advances · doi:10.1039/c7ra02642k · Cited by 9
Chirumbolo, S., & Bjørklund, G. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.12.061 · Cited by 9
Nrf2 in human cancers: biological significance and therapeutic potential
Tian, Y. (2024) · American Journal of Cancer Research · doi:10.62347/lzvo6743 · Cited by 9
New insights into the mechanism of Keap1-Nrf2 interaction based on cancer-associated mutations
Cheng, L., Wang, H., Li, S., Liu, Z., & Wang, C. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119791 · Cited by 8
Chen, J., Su, S., Pickar‐Oliver, A., Chiarella, A. M., Hahn, Q., Goldfarb, D., Cloer, E. W., Small, G. W., Sivashankar, S., Ramsden, D. A., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae761 · Cited by 8
Self-citationKhan, H., Killoran, R. C., Brickenden, A. M., Fan, J., Yang, D., & Choy, W. (2015) · Biochemical Journal · doi:10.1042/bj20140761 · Cited by 8
Guan, L., Torres‐Saavedra, P. A., Zhao, X., Major, M. B., Holmes, B., Nguyen, N. K., Kumaravelu, P., Hodge, T., Diehn, M., Zevallos, J. P., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2334 · Cited by 11
Self-citationThe Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Gopal, P., Yard, B. D., Petty, A. P., Lal, J. C., Bera, T. K., Hoang, T. Q., Buhimschi, A. D., & Abazeed, M. E. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1914 · Cited by 10
Soozangar, N., Sadeghi, M. R., Jeddi, F., Samadi, N., Hejazi, M. S., Azad, M., Shirmohamadi, M., & Somi, M. H. (2019) · Gazzetta Medica Italiana Archivio per le Scienze Mediche · doi:10.23736/s0393-3660.18.03799-3 · Cited by 5
Mechanisms and Markers of Clinical Radioresistance
Binkley, M. S., Diehn, M., Eke, I., & Willers, H. (2020) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-49701-9_4 · Cited by 6
SMARCA4 supports the oncogenic landscape of KRAS -driven lung tumorsPreprint
Malik, S., Oshima, M., Roy, N., Kaushik, S., Kuvshinova, O., Wu, W., Greer, J. E., Green, S., McMahon, M., Jen, K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.18.043927 · Cited by 5
Lin, Z., Ashish, S., Huang, L., Li, S., Li, Y., Zhou, Y., & Gu, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1676797 · Cited by 6
de Klerk, D. J., de Keijzer, M. J., Franchi, L. P., Tian, J., Gureev, M., Ge, Y., Mesquita, B. S., Saelman, G., herteryck, I. V., Dias, L. M., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117620 · Cited by 3
Nrf2 Contributes to the Poor Prognosis and Chemoresistance
Syu, J.-P., Chi, J., & Kung, H. (2016) · InTech eBooks · doi:10.5772/65105 · Cited by 2
The Keap1-Nrf2 Signaling Pathway in Lung Cancer
Raghunath, A., Raju, N., & Sundarraj, K. (2021) · Springer eBooks · doi:10.1007/978-981-33-6827-9_30 · Cited by 2
Coppée, R., Jeffares, D. C., Sabbagh, A., & Clain, J. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/346668 · Cited by 2
Matovina, M., Paić, A. T., Tomić, S., Brkić, H., Horvat, L. L., Barbarić, L., Filić, V., Pinterić, M., Jurić, S., & Kussayeva, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814178 · Cited by 1
Targeting Nrf2 in inflammation and cancer
Cowan, J. (2014) · UEA Digital Repository (University of East Anglia) · Cited by 1
Fox, D. B., Lupo, R., Noteware, L. C., Newcomb, R., Liu, J., Locasale, J. W., Hirschey, M. D., & Alvarez, J. V. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/513994 · Cited by 1
Metabolic Reprogramming by Histone Deacetylase Inhibition Selectively Targets NRF2-activated tumorsPreprint
Karagiannis, D., Wu, W., Li, A. M., Hayashi, M., Chen, X., Yip, M., Mangipudy, V. S., Xu, X., Rivera, F. J. S., Soto‐Feliciano, Y. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.24.538118 · Cited by 1
REGULATION OF THE OXIDATIVE STRESS RESPONSE BY ARID1A
Kwan, S. Y. (2015) · Digital Commons-TMC (Texas Medical Center)
Exome sequencing and human disease : the molecular characterisation of genetic disorders
Walsh, D. M. (2016) · University of Birmingham Institutional Research Archive (University of Birmingham)
PROTEOMIC DISSECTION OF KEAP1/NRF2 SIGNALING TO DETERMINE NEW PATHWAY INTERACTORS IN CANCER
Mulvaney, K. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/7v3v-x224
Modulators of Nrf2 Activation During Inflammation
Braidy, N. (2020) · Progress in inflammation research · doi:10.1007/978-3-030-44599-7_8
Saladi, S. V., & Ellisen, L. W. (2015) · Springer eBooks · doi:10.1007/978-3-319-17942-1_13
Supplementary Data 2 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Gopal, P., Yard, B. D., Petty, A. P., Lal, J. C., Bera, T. K., Hoang, T. Q., Buhimschi, A. D., & Abazeed, M. E. (2023) · doi:10.1158/1078-0432.22489107
Osman, A. A., Arslan, E., Bartels, M. D., Michikawa, C., Lindemann, A., Tomczak, K. J., Yu, W., Sandulache, V. C., Ma, W., Shen, L., et al. (2023) · doi:10.1158/1078-0432.c.6533191.v2
Lin, Z., Ashish, S., Huang, L., Li, S., Li, Y., Zhou, Y., & Gu, J. (2025) · Research Square · doi:10.21203/rs.3.rs-6458808/v1
Shukla, K., Castro, J., Cheng, D., Holley, L., & Brunk, E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.05.723010
Xu, Y., Ye, X., Lin, J., Guo, X., & Liu, Z. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112664
Choi, H. Y., Kwon, H., & Hah, Y. (2026) · Antioxidants · doi:10.3390/antiox15101223
Tumor cell–intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer
Fröse, J., Chen, E., Whittaker, C. A., Leclerc, P., Doherty, S., Langenbucher, A., Shao, J., Hellinger, R. D., Goulet, D. R., Tammela, T., et al. (2026) · Science Advances · doi:10.1126/sciadv.aeh8973 · Cited by 1
Gómez-Galán, M., Gil‐Martínez, J., de Juan, V. G., Bizkarguenaga, M., León-Barberena, J., Navarro‐Corcuera, A., Embade, N., Fernández‐Ramos, D., Lopitz‐Otsoa, F., lu, S., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10150900/v1
Metadata
- Authors
- Hast, B. E., Cloer, E. W., Goldfarb, D., Li, H., Siesser, P. F., Yan, F., Walter, V., Zheng, N., Hayes, D. N., & Major, M. B.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Major, Michael B.
- ORCID
- Venue
- Cancer Research
- Published
- 2014-02-01
- Volume
- 74
- Issue
- 3
- Pages
- 808-817
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC3932503
- OpenAlex
- W2164442171
- Cited by
- 138
- References
- 45
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 10 · 2023: 16 · 2022: 7 · 2021: 7 · 2020: 18 · 2019: 15 · 2018: 13 · 2017: 12 · 2016: 12 · 2015: 11 · 2014: 5
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion, public-domain)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, public-domain)
- UNC Libraries
- Funders
- Howard Hughes Medical Institute
- Golfers Against Cancer
- National Institutes of Health (1dp2od007149-01)
- National Cancer Institute (U24CA143848, T32-CA09475, T32CA009475, T32CA071341)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Keywords
- Keap1, Nrf2, somatic mutations, lung squamous cell carcinoma, E3 ubiquitin ligase, proteasomal degradation, ubiquitination, protein-protein binding, CUL3, tumor suppressor, passenger mutations
- MeSH terms
- Kelch-Like ECH-Associated Protein 1, Humans, Models, Molecular, Mutation, Neoplasms, Protein Binding, Protein Conformation, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, NF-E2-Related Factor 2, Ubiquitination, Protein Multimerization, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
